{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:36:30Z","timestamp":1791117390850,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1038\/ncpneph0660","type":"journal-article","created":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T13:18:01Z","timestamp":1195651081000},"page":"654-668","source":"Crossref","is-referenced-by-count":295,"title":["What nephrologists need to know about gadolinium"],"prefix":"10.1038","volume":"3","author":[{"given":"Jeffrey G","family":"Penfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert F","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneph0660_CR1","first-page":"1041","volume":"4","author":"JM Caille","year":"1983","unstructured":"Caille JM et al. (1983) Gadolinium as a contrast agent for NMR. AJNR Am J Neuroradiol 4: 1041\u20131042","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Suppl 1","key":"BFncpneph0660_CR2","first-page":"S2","volume":"27","author":"MF Tweedle","year":"1992","unstructured":"Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27 (Suppl 1): S2\u2013S6","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1148\/radiology.166.3.3340763","volume":"166","author":"JC Bousquet","year":"1988","unstructured":"Bousquet JC et al. (1988) Gd-DOTA: characterization of a new paramagnetic complex. Radiology 166: 693\u2013698","journal-title":"Radiology"},{"key":"BFncpneph0660_CR4","unstructured":"AuntMinnie.com (online 21 February 2007) IMV Report: MRI market growing. [ http:\/\/www.auntminnie.com\/index.asp?Sec=sup&Sub=bai&Pag=dis&ItemId=74472 ] (accessed 19 June 2007)"},{"key":"BFncpneph0660_CR5","first-page":"1654","volume":"14","author":"HS Thomsen","year":"2004","unstructured":"Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14: 1654\u20131656","journal-title":"Eur Radiol"},{"key":"BFncpneph0660_CR6","unstructured":"US Food and Drug Administration (online 23 May 2007) Healthcare professional sheet: gadolinium-containing contrast agents for magnetic resonance imaging (MRI) (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance). [ http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/gccaHCP.htm ] (accessed 19 June 2007)"},{"key":"BFncpneph0660_CR7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s003300050894","volume":"9","author":"SK Morcos","year":"1999","unstructured":"Morcos SK et al. (1999) Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 9: 1602\u20131613","journal-title":"Eur Radiol"},{"key":"BFncpneph0660_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","volume":"195","author":"B Hamm","year":"1995","unstructured":"Hamm B et al. (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195: 785\u2013792","journal-title":"Radiology"},{"key":"BFncpneph0660_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1148\/radiology.207.2.9577506","volume":"207","author":"RB Lauffer","year":"1998","unstructured":"Lauffer RB et al. (1998) MS-325: albumin-targeted contrast agent for MR angiography. Radiology 207: 529\u2013538","journal-title":"Radiology"},{"key":"BFncpneph0660_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/00004424-199811000-00003","volume":"33","author":"MA Kirchin","year":"1998","unstructured":"Kirchin MA et al. (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33: 798\u2013809","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0730-725X(90)90055-7","volume":"8","author":"WP Cacheris","year":"1990","unstructured":"Cacheris WP et al. (1990) The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8: 467\u2013481","journal-title":"Magn Reson Imaging"},{"key":"BFncpneph0660_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447.x","volume":"20","author":"JM Idee","year":"2006","unstructured":"Idee JM et al. (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20: 563\u2013576","journal-title":"Fundam Clin Pharmacol"},{"key":"BFncpneph0660_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00004424-199612000-00001","volume":"31","author":"NR Puttagunta","year":"1996","unstructured":"Puttagunta NR et al. (1996) Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 31: 739\u2013742","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cmmi.100","volume":"1","author":"S Laurent","year":"2006","unstructured":"Laurent S et al. (2006) Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1: 128\u2013137","journal-title":"Contrast Media Mol Imaging"},{"key":"BFncpneph0660_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0730-725X(92)90380-I","volume":"10","author":"MF Bellin","year":"1992","unstructured":"Bellin MF et al. (1992) Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10: 115\u2013118","journal-title":"Magn Reson Imaging"},{"key":"BFncpneph0660_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s003300050643","volume":"9","author":"FD Hammer","year":"1999","unstructured":"Hammer FD et al. (1999) Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 9: 128\u2013136","journal-title":"Eur Radiol"},{"key":"BFncpneph0660_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1148\/radiology.212.1.r99jl15280","volume":"212","author":"JA Kaufman","year":"1999","unstructured":"Kaufman JA et al. (1999) Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency\u2014early experience. Radiology 212: 280\u2013284","journal-title":"Radiology"},{"key":"BFncpneph0660_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/jmri.1880060129","volume":"6","author":"MR Prince","year":"1996","unstructured":"Prince MR et al. (1996) Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 6: 162\u2013166","journal-title":"J Magn Reson Imaging"},{"key":"BFncpneph0660_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/ndt\/17.5.824","volume":"17","author":"J Rieger","year":"2002","unstructured":"Rieger J et al. (2002) Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17: 824\u2013828","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0660_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1148\/radiology.180.1.2052729","volume":"180","author":"NM Rofsky","year":"1991","unstructured":"Rofsky NM et al. (1991) Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 180: 85\u201389","journal-title":"Radiology"},{"key":"BFncpneph0660_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00270-001-0083-x","volume":"25","author":"T Sancak","year":"2002","unstructured":"Sancak T et al. (2002) Gadodiamide as an alternative contrast agent in intravenous digital subtraction angiography and interventional procedures of the upper extremity veins. Cardiovasc Intervent Radiol 25: 49\u201352","journal-title":"Cardiovasc Intervent Radiol"},{"key":"BFncpneph0660_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1051-0443(07)61275-5","volume":"11","author":"DJ Spinosa","year":"2000","unstructured":"Spinosa DJ et al. (2000) Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11: 35\u201343","journal-title":"J Vasc Interv Radiol"},{"key":"BFncpneph0660_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1148\/radiology.210.3.r99fe58663","volume":"210","author":"DJ Spinosa","year":"1999","unstructured":"Spinosa DJ et al. (1999) Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. Radiology 210: 663\u2013672","journal-title":"Radiology"},{"key":"BFncpneph0660_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/ajkd.2000.19836","volume":"36","author":"RR Townsend","year":"2000","unstructured":"Townsend RR et al. (2000) Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 36: 1207\u20131212","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0660_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ccd.20592","volume":"67","author":"C Briguori","year":"2006","unstructured":"Briguori C (2006) Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67: 175\u2013180","journal-title":"Catheter Cardiovasc Interv"},{"key":"BFncpneph0660_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/ndt\/gfi304","volume":"21","author":"I Ergun","year":"2006","unstructured":"Ergun I et al. (2006) The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21: 697\u2013700","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0660_CR27","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfh272","volume":"19","author":"CM Erley","year":"2004","unstructured":"Erley CM et al. (2004) Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 19: 2526\u20132531","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0660_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0741-5214(03)00315-X","volume":"38","author":"AD Sam","year":"2003","unstructured":"Sam AD et al. (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38: 313\u2013318","journal-title":"J Vasc Surg"},{"key":"BFncpneph0660_CR29","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.5858\/2006-130-1354-AGCMNA","volume":"130","author":"H Akgun","year":"2006","unstructured":"Akgun H et al. (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130: 1354\u20131357","journal-title":"Arch Pathol Lab Med"},{"key":"BFncpneph0660_CR30","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1007\/s00330-002-1628-3","volume":"12","author":"HS Thomsen","year":"2002","unstructured":"Thomsen HS et al. for the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12: 2600\u20132605","journal-title":"Eur Radiol"},{"key":"BFncpneph0660_CR31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"SE Cowper","year":"2000","unstructured":"Cowper SE et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000\u20131001","journal-title":"Lancet"},{"key":"BFncpneph0660_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.ajkd.2005.06.024","volume":"46","author":"SR Daram","year":"2005","unstructured":"Daram SR et al. (2005) Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 46: 754\u2013759","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0660_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-4632.2005.02701.x","volume":"45","author":"TB Cassis","year":"2006","unstructured":"Cassis TB et al. (2006) Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 45: 56\u201359","journal-title":"Int J Dermatol"},{"key":"BFncpneph0660_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","volume":"21","author":"T Grobner","year":"2006","unstructured":"Grobner T (2006) Gadolinium\u2014a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104\u20131108","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0660_CR35","unstructured":"Danish Medicines Agency (online 29 May 2006) Investigation of the safety of MRI contrast medium Omniscan [press release]. [ http:\/\/www.dkma.dk\/1024\/visUKLSArtikel.asp?artikelID=8931 ]"},{"key":"BFncpneph0660_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/028418501127346756","volume":"42","author":"S Okada","year":"2001","unstructured":"Okada S et al. (2001) Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 42: 339\u2013341","journal-title":"Acta Radiol"},{"key":"BFncpneph0660_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2215\/CJN.03921106","volume":"2","author":"A Deo","year":"2007","unstructured":"Deo A et al. (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2: 264\u2013267","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0660_CR38","unstructured":"Centers for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents\u2014St Louis, Missouri, 2002\u20132006. MMWR Morb Mortal Wkly Rep 56: 137\u2013141"},{"key":"BFncpneph0660_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1076-6332(98)80191-8","volume":"5","author":"P Joffe","year":"1998","unstructured":"Joffe P et al. (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5: 491\u2013502","journal-title":"Acad Radiol"},{"key":"BFncpneph0660_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/01.rli.0000253505.88945.d5","volume":"42","author":"A Khurana","year":"2007","unstructured":"Khurana A et al. (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42: 139\u2013145","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR41","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1681\/ASN.2006060601","volume":"17","author":"P Marckmann","year":"2006","unstructured":"Marckmann P et al. (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359\u20132362","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0660_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/02841850701370717","volume":"48","author":"HS Thomsen","year":"2007","unstructured":"Thomsen HS et al. (2007) Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 48: 593\u2013596","journal-title":"Acta Radiol"},{"key":"BFncpneph0660_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2214\/AJR.06.1094","volume":"188","author":"DR Broome","year":"2007","unstructured":"Broome DR et al. (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188: 586\u2013592","journal-title":"AJR Am J Roentgenol"},{"key":"BFncpneph0660_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1148\/radiol.2431062144","volume":"243","author":"EA Sadowski","year":"2007","unstructured":"Sadowski EA et al. (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243: 148\u2013157","journal-title":"Radiology"},{"key":"BFncpneph0660_CR45","doi-asserted-by":"crossref","unstructured":"Marckmann P et al. (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant [10.1093\/ndt\/gfm261]","DOI":"10.1093\/ndt\/gfm261"},{"key":"BFncpneph0660_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ncpneph0373","volume":"3","author":"AS Weiss","year":"2007","unstructured":"Weiss AS et al. (2007) A case of nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 3: 111\u2013115","journal-title":"Nat Clin Pract Nephrol"},{"key":"BFncpneph0660_CR47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/01.rli.0000112789.57341.01","volume":"39","author":"WA Gibby","year":"2004","unstructured":"Gibby WA et al. (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39: 138\u2013142","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR48","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.rli.0000186569.32408.95","volume":"41","author":"GW White","year":"2006","unstructured":"White GW et al. (2006) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41: 272\u2013278","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","volume":"56","author":"WA High","year":"2007","unstructured":"High WA et al. (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21\u201326","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR50","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaad.2007.01.022","volume":"56","author":"WA High","year":"2007","unstructured":"High WA et al. (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 710\u2013712","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2006.10.048","volume":"56","author":"AS Boyd","year":"2007","unstructured":"Boyd AS et al. (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27\u201330","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00467-003-1380-1","volume":"19","author":"SM Jain","year":"2004","unstructured":"Jain SM et al. (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19: 467\u2013470","journal-title":"Pediatr Nephrol"},{"key":"BFncpneph0660_CR53","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/j.1600-6143.2005.00861.x","volume":"5","author":"U P\u00f6ge","year":"2005","unstructured":"P\u00f6ge U et al. (2005) MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 5: 1306\u20131311","journal-title":"Am J Transplant"},{"key":"BFncpneph0660_CR54","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.tp.0000228888.31242.2b","volume":"82","author":"M Cantarovich","year":"2006","unstructured":"Cantarovich M et al. (2006) Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. Transplantation 82: 433\u2013436","journal-title":"Transplantation"},{"key":"BFncpneph0660_CR55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","volume":"35","author":"FA Mendoza","year":"2006","unstructured":"Mendoza FA et al. (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238\u2013249","journal-title":"Semin Arthritis Rheum"},{"key":"BFncpneph0660_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","volume":"15","author":"SE Cowper","year":"2003","unstructured":"Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15: 785\u2013790","journal-title":"Curr Opin Rheumatol"},{"key":"BFncpneph0660_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2133.2005.06434.x","volume":"152","author":"M Gilliet","year":"2005","unstructured":"Gilliet M et al. (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152: 531\u2013536","journal-title":"Br J Dermatol"},{"key":"BFncpneph0660_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/mus.20153","volume":"30","author":"JM Levine","year":"2004","unstructured":"Levine JM et al. (2004) Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30: 569\u2013577","journal-title":"Muscle Nerve"},{"key":"BFncpneph0660_CR59","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1365-2133.2003.05181.x","volume":"148","author":"V Hubbard","year":"2003","unstructured":"Hubbard V et al. (2003) Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 148: 563\u2013568","journal-title":"Br J Dermatol"},{"key":"BFncpneph0660_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1067\/mjd.2003.78","volume":"48","author":"JM Mackay-Wiggan","year":"2003","unstructured":"Mackay-Wiggan JM et al. (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48: 55\u201360","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1067\/mjd.2003.77","volume":"48","author":"BN Streams","year":"2003","unstructured":"Streams BN et al. (2003) Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 48: 42\u201347","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0002-9343(03)00085-8","volume":"114","author":"RD Swartz","year":"2003","unstructured":"Swartz RD et al. (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114: 563\u2013572","journal-title":"Am J Med"},{"key":"BFncpneph0660_CR63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5858\/2006-130-209-MIINFD","volume":"130","author":"SE Gibson","year":"2006","unstructured":"Gibson SE et al. (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130: 209\u2013212","journal-title":"Arch Pathol Lab Med"},{"key":"BFncpneph0660_CR64","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/art.20362","volume":"50","author":"SA Jimenez","year":"2004","unstructured":"Jimenez SA et al. (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50: 2660\u20132666","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"BFncpneph0660_CR65","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jaad.2005.04.024","volume":"54","author":"C Kucher","year":"2006","unstructured":"Kucher C et al. (2006) Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54 (Suppl 2): S31\u2013S34","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0660_CR66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.139.7.903","volume":"139","author":"WW Ting","year":"2003","unstructured":"Ting WW et al. (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139: 903\u2013906","journal-title":"Arch Dermatol"},{"key":"BFncpneph0660_CR67","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/00000372-200306000-00004","volume":"25","author":"PW Baron","year":"2003","unstructured":"Baron PW et al. (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25: 204\u2013209","journal-title":"Am J Dermatopathol"},{"key":"BFncpneph0660_CR68","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.0303-6987.2004.00177.x","volume":"31","author":"K Hershko","year":"2004","unstructured":"Hershko K et al. (2004) A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodeling? J Cutan Pathol 31: 262\u2013265","journal-title":"J Cutan Pathol"},{"key":"BFncpneph0660_CR69","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.0303-6987.2005.00277.x","volume":"32","author":"DP Ruiz-Genao","year":"2005","unstructured":"Ruiz-Genao DP et al. (2005) Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol 32: 172\u2013175","journal-title":"J Cutan Pathol"},{"key":"BFncpneph0660_CR70","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2133.2006.07652.x","volume":"156","author":"M Edward","year":"2007","unstructured":"Edward M et al. (2007) Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol 156: 473\u2013479","journal-title":"Br J Dermatol"},{"key":"BFncpneph0660_CR71","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.0303-6987.2005.00365.x","volume":"32","author":"C Kucher","year":"2005","unstructured":"Kucher C et al. (2005) Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32: 484\u2013490","journal-title":"J Cutan Pathol"},{"key":"BFncpneph0660_CR72","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archderm.140.11.1322","volume":"140","author":"R Kafi","year":"2004","unstructured":"Kafi R et al. (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140: 1322\u20131324","journal-title":"Arch Dermatol"},{"key":"BFncpneph0660_CR73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2215\/CJN.03250906","volume":"2","author":"P Yerram","year":"2007","unstructured":"Yerram P et al. (2007) Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure\u2014role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2: 258\u2013263","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0660_CR74","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1365-2133.2003.05795.x","volume":"150","author":"HJ Chung","year":"2004","unstructured":"Chung HJ and Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150: 596\u2013597","journal-title":"Br J Dermatol"},{"key":"BFncpneph0660_CR75","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/jmri.1880050418","volume":"5","author":"PL Choyke","year":"1995","unstructured":"Choyke PL et al. (1995) Clearance of gadolinium chelates by hemodialysis: an in vitro study. J Magn Reson Imaging 5: 470\u2013472","journal-title":"J Magn Reson Imaging"},{"key":"BFncpneph0660_CR76","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/ndt\/10.7.1228","volume":"10","author":"J Dorsam","year":"1995","unstructured":"Dorsam J et al. (1995) Elimination of gadolinium-DTPA by peritoneal dialysis. Nephrol Dial Transplant 10: 1228\u20131230","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0660_CR77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1272\/jnms.70.12","volume":"70","author":"S Okada","year":"2003","unstructured":"Okada S et al. (2003) Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dialyzability. J Nippon Med Sch 70: 12\u201315","journal-title":"J Nippon Med Sch"},{"key":"BFncpneph0660_CR78","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11604-006-0055-9","volume":"24","author":"T Saitoh","year":"2006","unstructured":"Saitoh T et al. (2006) Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24: 445\u2013451","journal-title":"Radiat Med"},{"key":"BFncpneph0660_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/00004424-199111000-00009","volume":"26","author":"G Schuhmann-Giampieri","year":"1991","unstructured":"Schuhmann-Giampieri G and Krestin G (1991) Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 26: 975\u2013979","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR80","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/(SICI)1522-2586(199902)9:2<317::AID-JMRI25>3.0.CO;2-B","volume":"9","author":"SK Swan","year":"1999","unstructured":"Swan SK et al. (1999) Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 9: 317\u2013321","journal-title":"J Magn Reson Imaging"},{"key":"BFncpneph0660_CR81","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00004424-199907000-00001","volume":"34","author":"SK Swan","year":"1999","unstructured":"Swan SK et al. (1999) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34: 443\u2013448","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0720-048X(98)00090-4","volume":"31","author":"J Ueda","year":"1999","unstructured":"Ueda J et al. (1999) Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. Eur J Radiol 31: 76\u201380","journal-title":"Eur J Radiol"},{"key":"BFncpneph0660_CR83","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/00004424-199810000-00004","volume":"33","author":"J Ueda","year":"1998","unstructured":"Ueda J et al. (1998) Permeability of gadolinium-DTPA through two types of hemodialysis membrane. Invest Radiol 33: 734\u2013737","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR84","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.5858\/2004-128-1151-SHAOOO","volume":"128","author":"J Emerson","year":"2004","unstructured":"Emerson J and Kost G (2004) Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. Arch Pathol Lab Med 128: 1151\u20131156","journal-title":"Arch Pathol Lab Med"},{"key":"BFncpneph0660_CR85","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0731-7085(99)00188-0","volume":"21","author":"J Lin","year":"1999","unstructured":"Lin J et al. (1999) Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 21: 931\u2013943","journal-title":"J Pharm Biomed Anal"},{"key":"BFncpneph0660_CR86","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.rli.0000170447.45577.5e","volume":"40","author":"A Lowe","year":"2005","unstructured":"Lowe A et al. (2005) Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. Invest Radiol 40: 521\u2013525","journal-title":"Invest Radiol"},{"key":"BFncpneph0660_CR87","first-page":"165","volume":"8","author":"CD Moore","year":"2006","unstructured":"Moore CD et al. (2006) Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature. Rev Urol 8: 165\u2013168","journal-title":"Rev Urol"},{"key":"BFncpneph0660_CR88","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1148\/radiol.2273012007","volume":"227","author":"MR Prince","year":"2003","unstructured":"Prince MR et al. (2003) Gadodiamide administration causes spurious hypocalcemia. Radiology 227: 639\u2013646","journal-title":"Radiology"},{"key":"BFncpneph0660_CR89","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1309\/MGA3LC4X8CGLX9CH","volume":"121","author":"KA Proctor","year":"2004","unstructured":"Proctor KA et al. (2004) Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. Am J Clin Pathol 121: 282\u2013292","journal-title":"Am J Clin Pathol"},{"key":"BFncpneph0660_CR90","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3109\/00365519509104981","volume":"55","author":"PT Normann","year":"1995","unstructured":"Normann PT et al. (1995) Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 55: 421\u2013426","journal-title":"Scand J Clin Lab Invest"},{"key":"BFncpneph0660_CR91","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1373\/clinchem.2003.028886","volume":"50","author":"HP Kang","year":"2004","unstructured":"Kang HP et al. (2004) Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. Clin Chem 50: 741\u2013746","journal-title":"Clin Chem"},{"key":"BFncpneph0660_CR92","unstructured":"Medicines and Healthcare products Regulatory Agency (online 7 February 2007) Public assessment report: increased risk of nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. [ http:\/\/www.mhra.gov.uk\/home\/idcplg?IdcService=SS_GET_PAGE&ssDocName=CON2030229&ssSourceNodeId=\u00a0221&ssTargetNodeId=221 ]"},{"key":"BFncpneph0660_CR93","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2214\/AJR.06.1616","volume":"188","author":"E Kanal","year":"2007","unstructured":"Kanal E et al. (2007) ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188: 1447\u20131474","journal-title":"AJR Am J Roentgenol"},{"key":"BFncpneph0660_CR94","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.2214\/AJR.07.6610","volume":"188","author":"A Van Moore Jr","year":"2007","unstructured":"Van Moore A Jr (2007) Commentary on \u201cACR guidance document for safe MR practices: 2007\u201d. AJR Am J Roentgenol 188: 1446","journal-title":"AJR Am J Roentgenol"},{"key":"BFncpneph0660_CR95","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1148\/radiol.2423061640","volume":"242","author":"PH Kuo","year":"2007","unstructured":"Kuo PH et al. (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242: 647\u2013649","journal-title":"Radiology"},{"key":"BFncpneph0660_CR96","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461\u2013470","journal-title":"Ann Intern Med"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0660","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:19:50Z","timestamp":1684441190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["BFncpneph0660"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0660","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}